Mortality in necrotic form of erysipelas
DOI:
https://doi.org/10.34287/MMT.3(50).2021.4Abstract
Purpose of the study. To find out the mortality rate in patients with necrotic form of erysipelas and the reasons that cause it.
Materials and metods. 284 case histories of patients who were hospitalized in the center of purulent-septic surgery of KNP «City Hospital
№ 3» in Zaporozhye for the period 2016–2021 were analyzed.
Results. It is established that in the general population of the disease, 14,1% of patients suffer from the necrotic form of erysipelas. In the complex treatment of patients with surgical forms of erysipelas, the main place belongs to antibiotic therapy (ABT) and early surgical treatment of the area of the pathological process. Determination of procalcitonin in blood serum makes it possible to assess the progression of the inflammatory process and is a sensitive test for the effectiveness of treatment.
Conclusion. In 72,5% of cases, the disease was aggravated by sepsis with a mortality of 67,5%. The cause of mortality in patients with necrotic erythema is numerous irreversible changes in the internal organs.
References
Poljakova AS, Bakradze DM, Ivanov AV i dr. Diagnosticheskaja cennost' opredelenija urovnja prokal'citonina v praktike infekcionista. Voprosy sovremennoj pediatrii. 2017; 16: 334–41. https://vsp.spr-journal.ru› jour› article› download.
Gopaca GV, Ermakova LA. Rozha: sovremennoe sostojanie problemy. Nauchnyj al'manah. 2016; 1–2: 364–6. DOI: https://doi.org/10.23670/ IRJ.2018.72.6.012
Vitik AA, Shepel NP, Suhanova NV, Pylenko LN. Prediktory razvitija sepsisa i septicheskogo shoka. Vestnik intensivnoj tera- pii. 2017; 3: 63–8. https://dspace.uzhnu.edu.ua.
Falconeet M et al. Acute bacterial skin and skin structure infection sininternal medicine wards: old and new drugs. Internaland Emergency Medicine. 2016;1 (5): 637–48. https://pubmed. ncbi.nlm.nih.gov/27084183/.
BruunТet al. Early response in cellulitis: a prospective study of dynamics and predictors. Clinical Infectious Diseases.2016; 63 (8): 1034–41. https://pubmed.ncbi.nlm.nih.gov/27402819/.
De Jong JA, A van Oerset al. Efficacy and safety of procalcitonin guidance in reducing the duration of antibiotic treatment in critically ill patients: a randomised, controlled, open-label trial. The Lancet Infectious Diseases. 2016; 7: 1–9. https://pubmed.ncbi.nlm.nih.gov/26947523/.
Milcent Кet al. Use of Procalcitonin Assays to Predict Serious Bacterial Infection in Young Febrile Infants. JAMA Pediatr. 2016; 170 (1): 62–9. https://pubmed.ncbi.nlm.nih.gov/27088558/.
